Diabetes

The intricate relationship between carbohydrate consumption, diabetes, and obesity has emerged as a pressing public health concern worldwide. Excessive intake of refined carbs and sugars is strongly linked to rising obesity rates, insulin resistance, and type 2 diabetes. Nutrition experts emphasize that not all carbohydrates are equal: complex, fiber-rich carbs provide sustained energy and promote metabolic health, while ultra-processed carbohydrates contribute to rapid blood sugar spikes and weight gain.

Lupin Limited, a prominent Indian pharmaceutical company, has introduced a generic version of liraglutide injection in the United States. This medication, marketed under the brand name Victoza by Novo Nordisk, is indicated for improving glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus. The launch signifies Lupin's strategic entry into the glucagon-like peptide-1 (GLP-1) receptor agonist market, a class of drugs experiencing increased demand. The U.S.

A recent study by the Indian Council of Medical Research (ICMR) highlights the nation’s dietary imbalance, revealing that approximately 62% of daily caloric intake in India comes from carbohydrates. Nutrition experts warn that such high carbohydrate consumption, coupled with sedentary lifestyles, is contributing to escalating rates of type 2 diabetes, obesity, and related metabolic disorders. The study underscores the need for diversified diets incorporating proteins, healthy fats, and fiber-rich foods.

Recent Indian studies are redefining the conventional narrative around mango consumption and diabetes management. Traditionally, mangoes have been cautioned against for individuals with diabetes due to their natural sugar content. However, emerging research indicates that moderate intake of mangoes may not spike blood glucose levels as severely as previously thought.